Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders (2017 - 2026)

Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at $22.6 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 164.57% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89.2 million (up 673.74% YoY) and the FY2025 annual result came in at $75.1 million, up 610.66% from the prior year.
• Net Income towards Common Stockholders was $22.6 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $30.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $224.1 million in Q3 2022 and bottomed at -$276.1 million in Q4 2022.
• A 5-year average of -$6.4 million and a median of -$3.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 833.67% in 2022, while the deepest fall reached 526.61% in 2022.
• Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders stood at -$276.1 million in 2022, then surged by 69.93% to -$83.0 million in 2023, then jumped by 123.59% to $19.6 million in 2024, then jumped by 54.86% to $30.3 million in 2025, then dropped by 25.53% to $22.6 million in 2026.
• Business Quant data shows KNSA's Net Income towards Common Stockholders at $22.6 million in Q1 2026, $30.3 million in Q4 2025, and $18.4 million in Q3 2025.